BR0112521A - Indolquinazolinonas - Google Patents

Indolquinazolinonas

Info

Publication number
BR0112521A
BR0112521A BR0112521-4A BR0112521A BR0112521A BR 0112521 A BR0112521 A BR 0112521A BR 0112521 A BR0112521 A BR 0112521A BR 0112521 A BR0112521 A BR 0112521A
Authority
BR
Brazil
Prior art keywords
indolquinazolinones
compounds
formula
indolquinazolinonas
pharmaceuticals
Prior art date
Application number
BR0112521-4A
Other languages
English (en)
Portuguese (pt)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0112521A publication Critical patent/BR0112521A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
BR0112521-4A 2000-07-17 2001-07-16 Indolquinazolinonas BR0112521A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0017508.3A GB0017508D0 (en) 2000-07-17 2000-07-17 Antimicrobials
PCT/EP2001/008192 WO2002006284A1 (en) 2000-07-17 2001-07-16 Indoloquinazolinones

Publications (1)

Publication Number Publication Date
BR0112521A true BR0112521A (pt) 2003-07-01

Family

ID=9895801

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112521-4A BR0112521A (pt) 2000-07-17 2001-07-16 Indolquinazolinonas

Country Status (18)

Country Link
US (1) US6964960B2 (enExample)
EP (1) EP1303517B1 (enExample)
JP (1) JP3939246B2 (enExample)
CN (1) CN1183136C (enExample)
AR (1) AR031379A1 (enExample)
AT (1) ATE262530T1 (enExample)
AU (1) AU2001279754A1 (enExample)
BR (1) BR0112521A (enExample)
CA (1) CA2415683C (enExample)
DE (1) DE60102473T2 (enExample)
DK (1) DK1303517T3 (enExample)
ES (1) ES2218439T3 (enExample)
GB (1) GB0017508D0 (enExample)
MY (1) MY133969A (enExample)
PE (1) PE20020210A1 (enExample)
PT (1) PT1303517E (enExample)
TR (1) TR200401026T4 (enExample)
WO (1) WO2002006284A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
CN100398519C (zh) 2003-02-28 2008-07-02 伊诺泰克制药公司 四环苯甲酰胺衍生物及其用法
RU2007135362A (ru) 2005-02-25 2009-03-27 Инотек Фармасьютикалз Корпорейшн (Us) Тетрациклические амино- и карбоксамидосоединения и способ их применения
CN101316592A (zh) 2005-08-24 2008-12-03 伊诺泰克制药公司 茚并异喹啉酮类似物及其用法
EP2069351B1 (en) 2006-06-20 2015-10-28 AbbVie Inc. Pyrazoloquinazolinones as parp inhibitors
GB0615809D0 (en) * 2006-08-09 2006-09-20 Istituto Di Ricerche D Biolog Therapeutic compounds
GB0701273D0 (en) * 2007-01-24 2007-02-28 Angeletti P Ist Richerche Bio New compounds
MX2009009183A (es) 2007-02-28 2009-09-07 Inotek Pharmaceuticals Corp Analogos de indenoisoquinolinona y metodos de utilizacion de los mismos.
CA2686848A1 (en) 2007-05-08 2008-11-20 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
ES2562903T3 (es) 2011-07-13 2016-03-09 Santen Pharmaceutical Co., Ltd Nuevo compuesto que tiene actividad inhibidora de PARP
CN102766144B (zh) * 2012-07-10 2014-04-23 浙江大学 一种吲哚并[1,2-c]喹唑啉化合物的制备方法
WO2017013237A1 (en) 2015-07-23 2017-01-26 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2019175132A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
US20220073531A1 (en) * 2018-11-30 2022-03-10 Merck Patent Gmbh Compounds for electronic devices
CN113544132A (zh) * 2019-03-12 2021-10-22 默克专利有限公司 用于有机电致发光器件的材料
CN110357892B (zh) * 2019-07-10 2022-06-07 云南大学 四氢嘧啶并[1,2-a]吲哚衍生物及其合成方法与应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN114195789B (zh) * 2021-12-15 2022-09-09 广东海洋大学 一种无金属参与的多环吲哚衍生物的制备方法
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635966A (en) 1969-10-22 1972-01-18 Robins Co Inc A H 6-substituted-indolo(1 2-c)quinazolines
DE2237372C3 (de) 1972-07-29 1981-07-09 Basf Ag, 6700 Ludwigshafen Heterocyclische Farbstoffe, ihre Herstellung und ihre Verwendung
US5441955A (en) 1993-11-19 1995-08-15 Pathogenesis Corporation Indolo[2,1-biquinazoline-6,12-dione antibacterial compounds and methods of use thereof
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues

Also Published As

Publication number Publication date
CA2415683C (en) 2009-12-29
ATE262530T1 (de) 2004-04-15
JP2004504323A (ja) 2004-02-12
AU2001279754A1 (en) 2002-01-30
DE60102473D1 (de) 2004-04-29
HK1055426A1 (en) 2004-01-09
EP1303517A1 (en) 2003-04-23
PE20020210A1 (es) 2002-04-04
HK1056872A1 (en) 2004-03-05
DK1303517T3 (da) 2004-06-21
GB0017508D0 (en) 2000-08-30
US6964960B2 (en) 2005-11-15
JP3939246B2 (ja) 2007-07-04
TR200401026T4 (tr) 2004-07-21
WO2002006284A1 (en) 2002-01-24
AR031379A1 (es) 2003-09-24
CN1441803A (zh) 2003-09-10
DE60102473T2 (de) 2005-02-03
CN1183136C (zh) 2005-01-05
CA2415683A1 (en) 2002-01-24
US20030199502A1 (en) 2003-10-23
EP1303517B1 (en) 2004-03-24
PT1303517E (pt) 2004-07-30
MY133969A (en) 2007-11-30
ES2218439T3 (es) 2004-11-16

Similar Documents

Publication Publication Date Title
BR0115605A (pt) Derivados de naftaleno
BR0108678A (pt) Novos compostos
BR0214666A (pt) Derivados de acetileno tendo atividade antagonìstica de mglur5
BR0208338A (pt) Derivados de piridina
BRPI0419305B8 (pt) compostos inibidores de p38, composições farmacêuticas compreendendo os mesmos e usos dos referidos compostos na preparação de medicamentos
ATE270817T1 (de) Fungizide
SE0102616D0 (sv) Novel compounds
BR0110998A (pt) Derivados de fenilglicina
BR0116217A (pt) Quinolonas antimicrobianas, composição farmacêutica, bem como aplicação farmacêutica das referidas quinolonas
PT1193270E (pt) Pirrolobenzodiazepinas
BR0312129A (pt) Derivados de espiroindolinapiperidina
DK0944643T3 (da) Oxyiminopregnancarbolactoner.
BR0308211A (pt) Cumarinas úteis como biomarcadores
BRPI0412851A (pt) benzamidazóis de n-metila-substituìdos
BRPI0113162B8 (pt) compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos
BG103219A (bg) Бензамидинови производни и използването им като лекарствени средства с ltb4-антагонистично действие
IT1302264B1 (it) Derivati a struttura n-acil vanillinamidica in grado di attivare irecettori periferici dei cannabinoidi
SE9901077D0 (sv) Novel use
MY133969A (en) Indoloquinazolinones
DE60112956D1 (de) Kristalline formen von fluvastatin sodium
BR9916318A (pt) Compostos bicìclicos
BR0014990A (pt) Derivados de tetrahidrotiopirano ranftalazinona como inibidores de pde4
BR0208566A (pt) Derivados de beta-carbolina
SE9801494D0 (sv) Novel use
BR0213990A (pt) Derivados de piperazina tendo atividade antagonìstica de sst1

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements